Losartan side effects urinary frequency
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Urinary Frequency: Key Insights
Losartan’s Effects on Urinary Excretion and Frequency
Losartan, an angiotensin II receptor blocker, is known to increase the urinary excretion of uric acid and other purine bases. Studies in healthy subjects and patients have shown that after taking losartan, there is a significant rise in urine output and urinary excretion of uric acid, xanthine, and oxypurinol, especially within a few hours of administration. This increase in urine flow rate may lead to more frequent urination in some individuals, although the primary focus of these studies was on uric acid excretion rather than urinary frequency as a symptom Yamamoto2000Burnier1993Shahinfar1999.
Losartan and Bladder Function
Research in animal models has shown that losartan can influence bladder function. In aged rats with hypertension, losartan treatment reduced urine output, post-voiding residual urine volume, and bladder capacity, suggesting a potential role in improving bladder dysfunction. However, these findings are from animal studies, and direct evidence in humans regarding losartan causing or reducing urinary frequency is limited .
Clinical Observations and Safety
In clinical trials involving patients with kidney disease or hypertension, losartan has not been commonly associated with urinary frequency as a reported side effect. Most studies focus on its benefits in reducing proteinuria, preserving kidney function, and lowering serum uric acid levels. Adverse events related to the urinary tract, such as increased urination or urinary frequency, are not highlighted as significant concerns in these populations Bryant2021Lee2011Park2003+3 MORE.
Mechanisms Behind Increased Urine Output
The observed increase in urine flow rate after losartan administration is likely due to its effects on renal tubular transport and increased excretion of electrolytes and uric acid. This diuretic-like effect is more pronounced in certain conditions, such as low-salt diets or when combined with other medications affecting uric acid metabolism. However, this effect does not consistently translate to bothersome urinary frequency in most patients Yamamoto2000Burnier1993Shahinfar1999.
Conclusion
Losartan can increase urine output and uric acid excretion, which may occasionally lead to increased urinary frequency, especially shortly after dosing. However, urinary frequency is not a commonly reported or significant side effect in clinical studies involving losartan. Most evidence points to its renal protective effects and uric acid-lowering properties, with minimal impact on urinary frequency for the majority of patients Bryant2021Yamamoto2000Lee2011+7 MORE.
Sources and full results
Most relevant research papers on this topic
Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases.
Losartan potassium increases urinary excretion of uric acid, xanthine, and oxypurinol, potentially increasing the frequency of urinary tract calculi.
Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
Losartan significantly decreased proteinuria and urinary angiotensinogen excretion, preserving renal function in non-diabetic patients with chronic kidney disease.
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Losartan effectively reduces urinary protein and TGF-beta1 levels in IgA nephropathy patients, while amlodipine does not, potentially impacting their management.
DOI
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Losartan increases urinary sodium excretion in low-sodium diets, but has no significant effect on blood pressure, glomerular filtration rate, or renal blood flow in water-loaded subjects.
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
Losartan safely decreased serum uric acid and increased uric acid excretion without increasing urinary dihydrogen urate, the primary risk factor for acute urate nephropathy.
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Losartan may help reduce blood pressure and serum uric acid levels in renal transplant recipients treated with cyclosporin A, with less impact on serum potassium levels than enalapril.
DOI